Quarterly report · Q2
2934.TEDINET S100SM1Y
Period2023-06-01 → 2023-11-30
Filed2024-01-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.0bn | 2023-06-01 → 2023-11-30 | Cons. | Net sales |
| Revenue | ¥16.8bn | 2022-06-01 → 2023-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥9.1bn | 2022-06-01 → 2022-11-30 | Cons. | Net sales |
| Operating income | −¥221m | 2023-06-01 → 2023-11-30 | Cons. | Operating income |
| Operating income | −¥389m | 2022-06-01 → 2022-11-30 | Cons. | Operating income |
| Ordinary income | −¥232m | 2023-06-01 → 2023-11-30 | Cons. | Ordinary income |
| Ordinary income | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥403m | 2022-06-01 → 2022-11-30 | Cons. | Ordinary income |
| Profit before tax | −¥233m | 2023-06-01 → 2023-11-30 | Cons. | Income before income taxes |
| Profit before tax | −¥403m | 2022-06-01 → 2022-11-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥287m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.9bn | 2022-06-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥354m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥284m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss |
| Net income | −¥321m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss |
| Total assets | ¥7.4bn | at 2023-11-30 | Cons. | Assets |
| Total assets | ¥7.2bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥7.9bn | at 2022-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.2bn | at 2023-11-30 | Cons. | Liabilities |
| Total liabilities | ¥4.5bn | at 2023-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.1bn | at 2023-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.7bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥4.2bn | at 2022-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.3bn | at 2023-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.6bn | at 2023-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.3bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2023-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2022-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥971m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥594m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥300m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥800m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥933m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.5bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.3bn | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-59.33 | 2023-06-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-51.91 | 2023-09-01 → 2023-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-410.6 | 2022-06-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-77.42 | 2022-06-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-48.4 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 39.1% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.1% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.2% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2023-11-30 | −¥115m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2023-11-30 | −¥115m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2023-11-30 | −¥290m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥2.4bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥2.3bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥114m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥19m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥6m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥3.7bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥3.7bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥958,000 |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥44m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2023-11-30 | ¥8.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2023-11-30 | ¥8.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥115m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2023-11-30 | ¥69m |
| Reconciling Itemsreconciling | revenue | 2022-06-01 → 2022-11-30 | −¥84m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-06-01 → 2022-11-30 | −¥84m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2022-11-30 | −¥277m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥3.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥2.9bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥84m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥55m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥248m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥4.2bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥4.2bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥181,000 |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2022-06-01 → 2022-11-30 | −¥414m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2022-11-30 | ¥9.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2022-11-30 | ¥9.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥84m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2022-11-30 | −¥112m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 505
| Item | Context | Value | Unit |
|---|---|---|---|
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.2035 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 317600 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0646 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 123000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0250 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 81300 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0165 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 66500 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0135 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 44000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0090 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 42400 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0090 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 40000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0081 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 34400 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0070 | |
| Number of shares held | CurrentQuarterInstant | 4118200 | |
| Shareholding ratio | CurrentQuarterInstant | 0.8383 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 200100 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 4910100 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 49101 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 2798 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 5112998 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 49101 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 200100 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 200100 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0391 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 200100 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 200100 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0391 | |
| Cash and deposits | Prior1YearInstant | 1648360000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 1310289000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 1688506000 | JPY |
| Accounts receivable trade | CurrentQuarterInstant | 1559958000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 792674000 | JPY |
| Merchandise and finished goods | CurrentQuarterInstant | 1427502000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 51725000 | JPY |
| Raw materials and supplies | CurrentQuarterInstant | 32481000 | JPY |
| Work in process | Prior1YearInstant | 20558000 | JPY |
| Work in process | CurrentQuarterInstant | 39071000 | JPY |
| Prepaid expenses | Prior1YearInstant | 148301000 | JPY |
| Prepaid expenses | CurrentQuarterInstant | 164511000 | JPY |
| Short term loans receivable | Prior1YearInstant | 30000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |